Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
Genetically modified pig may hold keys to develop treatments for RP

Genetically modified pig may hold keys to develop treatments for RP

Dompé enters definitive agreement to acquire Anabasis

Dompé enters definitive agreement to acquire Anabasis

WSU's novel gene-therapy for blindness receives $250,000 FFB grant

WSU's novel gene-therapy for blindness receives $250,000 FFB grant

New gene therapy shows promise against X-linked retinitis pigmentosa

New gene therapy shows promise against X-linked retinitis pigmentosa

Dendrimers offers a new way to treat age-related macular degeneration, retinitis pigmentosa

Dendrimers offers a new way to treat age-related macular degeneration, retinitis pigmentosa

Potential nanoparticle treatment for macular degeneration and retinitis pigmentosa

Potential nanoparticle treatment for macular degeneration and retinitis pigmentosa

Retina Implant scientific advisory board approves multi-center phase of second human clinical trial

Retina Implant scientific advisory board approves multi-center phase of second human clinical trial

New protein in the fruit fly eye may shed light on neurodegenerative diseases

New protein in the fruit fly eye may shed light on neurodegenerative diseases

Clinical-grade viral vector can cure choroideremia

Clinical-grade viral vector can cure choroideremia

Argus II Retinal Prosthesis System successfully implanted in advanced Retinitis Pigmentosa patient

Argus II Retinal Prosthesis System successfully implanted in advanced Retinitis Pigmentosa patient

RetroSense, WSU sign license agreement for channelrhodopsin-based approaches

RetroSense, WSU sign license agreement for channelrhodopsin-based approaches

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

Novel bipartite gene therapy for retinitis pigmentosa

Novel bipartite gene therapy for retinitis pigmentosa

Two computerized tests increase ability to detect remaining vision in patients with RP

Two computerized tests increase ability to detect remaining vision in patients with RP

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

New collaboration reinforces Sanofi's translational discovery platform for retinal diseases

New collaboration reinforces Sanofi's translational discovery platform for retinal diseases

Contraceptive pill prevents loss of eye sight

Contraceptive pill prevents loss of eye sight

New genetic cause of retinitis pigmentosa

New genetic cause of retinitis pigmentosa

Researchers identify potential cause of hereditary, progressive blindness

Researchers identify potential cause of hereditary, progressive blindness

Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD

Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.